This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| PPT1 | |
|---|---|
| Name | PPT1 |
| Uniprot | PPT1_HUMAN |
| Location | Lysosome |
| Length | 306 aa |
| Organism | Homo sapiens |
PPT1 PPT1 is a human lysosomal enzyme implicated in inherited neurodegeneration and lipid metabolism, originally characterized in biochemical studies of infantile neuronal ceroid lipofuscinosis and subjects from genetic linkage cohorts. It has been studied in diverse contexts including clinical genetics, neuropathology, enzymology, and therapeutic development involving model organisms, patient advocacy groups, and regulatory agencies. PPT1 research intersects with investigations led by consortia studying lysosomal storage disorders, pediatric neurology networks, and translational programs at major biomedical centers.
PPT1 was identified through positional cloning efforts that involved collaborations among teams at institutions such as Harvard University, Johns Hopkins University, and the National Institutes of Health. Early literature linked PPT1 variants to phenotypes observed in cohorts at pediatric hospitals and referrals to specialty clinics associated with organizations like the Muscular Dystrophy Association and the European Society for Paediatric Neurology. Subsequent molecular work engaged laboratories at institutes including the Max Planck Society and the University of Cambridge, integrating proteomics platforms developed by groups at Stanford University and Massachusetts Institute of Technology.
The PPT1 gene was mapped using techniques employed by teams at the Wellcome Trust Sanger Institute and sequenced in studies that referenced databases curated by European Molecular Biology Laboratory groups. The coding sequence predicts a polypeptide with signal peptide motifs characterized in protein structural surveys from the Protein Data Bank and alignment studies from the National Center for Biotechnology Information. Crystallographic and cryo-EM efforts at centers like EMBL-EBI and the RCSB provided templates for homology models used by research groups at Columbia University and University of California, San Francisco. Domain architecture comparisons invoked datasets from the Human Protein Atlas and phylogenetic analyses performed at the University of Cambridge revealing conserved active site residues highlighted in studies by investigators at Yale University.
PPT1 encodes a palmitoyl-protein thioesterase that catalyzes depalmitoylation reactions studied in enzymology labs at institutions such as University College London and Oxford University. Biochemical assays developed in collaboration with groups at ETH Zurich and the Karolinska Institute measured activity on substrates characterized in lipidomics efforts at Cold Spring Harbor Laboratory and mass spectrometry cores at Imperial College London. Functional studies in neuronal culture systems used protocols established by laboratories at University of Pennsylvania and University of Toronto, while in vivo investigations employed knockout and transgenic models from repositories like the Jackson Laboratory and the European Mouse Mutant Archive.
Mutations in the PPT1 coding region were linked to infantile neuronal ceroid lipofuscinosis in clinical series reported by pediatric neurologists at Great Ormond Street Hospital and geneticists affiliated with the American College of Medical Genetics and Genomics. Natural history cohorts coordinated by networks such as the European Reference Network and the Undiagnosed Diseases Network documented phenotypes ranging from visual impairment to motor regression, with diagnostic confirmation performed in laboratories recognized by the College of American Pathologists and clinical genetics services at Mayo Clinic. Associations with modifier loci were explored through genome-wide studies at centers like the Broad Institute and consortium efforts including the International NCL Consortium.
Pathogenic variants identified in case series from specialized centers including Boston Children’s Hospital and The Hospital for Sick Children disrupt thioesterase activity, leading to accumulation of autofluorescent storage material characterized in ultrastructural studies at institutions such as the National Institute of Neurological Disorders and Stroke and the Institut Pasteur. Cellular mechanisms implicated include impaired lysosomal turnover and synaptic dysfunction documented in collaborative projects with research groups at Duke University and Vanderbilt University Medical Center. Animal model studies from teams at Cold Spring Harbor Laboratory and Institut de Myologie elucidated pathways involving protein trafficking and neuroinflammation that mirror findings reported by neuropathology units at UCLA and Johns Hopkins Hospital.
Diagnostic workflows originate from molecular diagnostic laboratories at the Molecular Genetics Laboratory associated with major hospitals and reference labs accredited by agencies like the Clinical Laboratory Improvement Amendments program. Techniques include targeted sequencing panels validated by centers such as the National Health Service genomic laboratories, exome and genome sequencing pipelines deployed by the Broad Institute, enzymatic activity assays standardized in clinical chemistry units at Mayo Clinic Laboratories, and neuropathological confirmation using electron microscopy protocols from pathology departments at Addenbrooke's Hospital. Newborn screening pilot studies have been coordinated by public health units in collaboration with organizations like the American Academy of Pediatrics.
Therapeutic strategies under investigation involve enzyme replacement, gene therapy, and small-molecule approaches pursued in translational programs at biopharmaceutical companies and academic spinouts incubated at Cambridge Biomedical Campus and Biogen-affiliated research sites. Clinical trials have been sponsored by consortia including networks connected to the National Institute of Child Health and Human Development and industry partners submitting protocols to regulatory bodies such as the Food and Drug Administration and the European Medicines Agency. Preclinical efficacy studies used viral vector platforms developed at University of California, Los Angeles and gene-editing techniques refined at laboratories like the Broad Institute, while patient-centered outcomes and registries have been organized by advocacy groups including the Batten Disease Support and Research Association and international patient networks.